Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents.
about
How Chemotherapy Increases the Risk of Systemic Candidiasis in Cancer Patients: Current Paradigm and Future DirectionsPlatinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS.Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendationsHypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS.Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancerA retrospective review of the frequency and nature of acute hypersensitivity reactions at a medium-sized infusion center: comparison to reported values and inconsistencies found in literature.Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and AlternativeChemotherapy Related Angioedema.Significance of Kampo, traditional Japanese medicine, in supportive care of cancer patientsRole of Kampo medicine in integrative cancer therapy.Gemcitabine-Related Pneumonitis in Pancreas Adenocarcinoma--An Infrequent Event: Elucidation of Risk Factors and Management ImplicationsSerum lactate dehydrogenase levels as a predictive marker of oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer.Single premedication dose of dexamethasone 20 mg IV before docetaxel administration.Adverse mucocutaneous reactions related to chemotherapeutic agents: part II.Desensitization regimens for drug allergy: state of the art in the 21st century.Dermatologic manifestations of cytotoxic therapy.IgE and chemotherapy.Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization.Incidence, clinical features and management of hypersensitivity reactions to chemotherapeutic drugs in children with cancer.Oxaliplatin-induced hypersensitivity reaction: underlying mechanisms and management.Treatment outcomes of rapid desensitisation protocols for chemotherapeutic agents and monoclonal antibodies following hypersensitivity reactions.Presentation and Diagnosis of Hypersensitivity to Platinum Drugs.Hypersensitivity to Carboplatin in Children with Malignancy.Dermatological adverse events with taxane chemotherapy.Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience.Atypical presentation of fever as hypersensitivity reaction to oxaliplatin.Evaluation of the effects and adverse drug reactions of low-dose dexamethasone premedication with weekly docetaxel.Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-HER2/neu] in Combination with Griseofulvin against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3).Do immunoglobulin G and immunoglobulin E anti-l-asparaginase antibodies have distinct implications in children with acute lymphoblastic leukemia? A cross-sectional studyHemoptysis and acute respiratory syndrome (ARDS) as delayed-type hypersensitivity after FOLFOX4 plus bevacizumab treatment.Becoming patient: a path to effective participation with chronic terminal cancer.Effectiveness of oxaliplatin desensitization protocols.Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: The Role of Desensitizations.The use of nanoparticulates to treat breast cancer.From the Children's Oncology Group: Evidence-Based Recommendations for PEG-Asparaginase Nurse Monitoring, Hypersensitivity Reaction Management, and Patient/Family Education.Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol.Successful desensitization protocol for hypersensitivity reaction probably caused by dabrafenib in a patient with metastatic melanoma.Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines.
P2860
Q26771113-7EFF1773-F6D2-4EA2-9696-2EEDA4E0E550Q33911016-4146E9DE-E15D-4F73-BEFF-E142D338ACD6Q33982751-34B6FBFC-F559-459A-B2BF-E2B77539F03BQ34039745-23A3A8A2-4DCA-437E-AB9E-16176C0E68F8Q34648284-5F167163-12AE-4CFF-BBBF-F409E6CDF637Q34648601-B1C0CF86-C0F6-4A6A-AF60-F4433A0A5AD0Q35892045-9E26D584-454E-4428-89BB-EE48C165AD78Q36972079-698BDF87-15C6-41F5-A420-A9F932E72CA2Q36990461-B2AAA8D8-2742-46D9-9BF4-B80CFE58C8DCQ37044478-152D68C7-6B49-49C2-83E3-5BC385C9DB50Q37168261-9F6B42C3-254B-4292-87FE-B86B0D9B9BD2Q37730274-6DE078CF-559E-4AD8-8551-8772D03D4FE8Q37744191-76921BA9-806B-4CF8-A385-F72C099511EBQ37820276-DBC3C836-BC08-41D4-9362-6D80D3A67AFFQ37924898-BF3BB707-8290-463B-8F56-A1F53007F30AQ37930714-7469D26F-C31C-4BD0-8399-D379F4609F34Q37964492-DA3B4346-9CB3-4241-B2D7-A388C357C4C2Q38009188-B5835379-28EF-4D40-93CA-278FAD7EAFE4Q38114361-1C2D1966-6DC5-44D2-BAE8-A48095302686Q38237316-5CB27DFF-1FAD-4E2B-9897-90E5A0FF4319Q38393480-616928D2-797F-45DC-9E35-BB83E82039ECQ38541188-0E49D359-B1E8-4669-9FDF-36CD2FB854EEQ38817913-ECAFA283-8B3A-4C21-AE08-2CFE4A185CBAQ38934447-E21807BA-0CE6-4B6D-BF9D-1279073E378CQ38968266-94879183-C792-4C45-81F3-1BA788D14701Q40184667-7D13F447-E928-4C8A-BC5A-161ECE7FC106Q40521965-8935AAD7-D340-47DE-84EA-97159AA61F21Q40678981-3EF0DFD7-8DFE-48CE-A107-F0FE80FEE1C0Q41491082-BAEA73D3-B3C1-4FD3-823C-442C403360F1Q41810095-35E3A974-85CA-405C-A457-2FC66005F008Q43435999-6C0C5179-62C7-4F64-91EA-B74A4D1FC9B6Q44080416-9BBA98D6-22D0-497F-9EC1-F06A11572EC4Q44842257-E92408D3-C39A-4A8F-A709-7050F2306240Q45066468-77A43266-B6A6-4E19-8C74-426D0BDC2BC3Q45162637-00AE7BE9-979A-4AC8-8F12-886494480C9EQ46006850-95D2A987-5D4E-482F-9F3D-AE028FF6E047Q47692465-47959E76-89AE-4556-B095-385E34D7A6A7Q50205188-263DDC73-EC29-4232-84A6-A72D02B61B14
P2860
Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Diagnosis and management of hy ...... on cancer chemotherapy agents.
@en
Diagnosis and management of hy ...... on cancer chemotherapy agents.
@nl
type
label
Diagnosis and management of hy ...... on cancer chemotherapy agents.
@en
Diagnosis and management of hy ...... on cancer chemotherapy agents.
@nl
prefLabel
Diagnosis and management of hy ...... on cancer chemotherapy agents.
@en
Diagnosis and management of hy ...... on cancer chemotherapy agents.
@nl
P2093
P1476
Diagnosis and management of hy ...... on cancer chemotherapy agents.
@en
P2093
Christina Lee
Mary Gianos
William B Klaustermeyer
P304
179-87; quiz 187-9, 222
P356
10.1016/S1081-1206(10)60078-6
P577
2009-03-01T00:00:00Z